Associations of ABO and rhesus d blood groups with phenome-wide disease incidence: a 41-year retrospective cohort study of 482,914 patients

  1. Peter Bruun-Rasmussen
  2. Morten Hanefeld Dziegiel
  3. Karina Banasik
  4. Pär Ingemar Johansson
  5. Søren Brunak  Is a corresponding author
  1. Copenhagen University Hospital, Denmark
  2. University of Copenhagen, Denmark

Abstract

Background: Whether natural selection may have attributed to the observed blood group frequency differences between populations remains debatable. The ABO system has been associated with several diseases and recently also with susceptibility to COVID-19 infection. Associative studies of the RhD system and diseases are sparser. A large disease-wide risk analysis may further elucidate the relationship between the ABO/RhD blood groups and disease incidence.

Methods: We performed a systematic log-linear quasi-Poisson regression analysis of the ABO/RhD blood groups across 1,312 phecode diagnoses. Unlike prior studies, we determined the incidence rate ratio foreach individual ABO blood group relative to all other ABO blood groups as opposed to using blood group O as the reference. Moreover, we used up to 41-years of nationwide Danish follow-up data, and a disease categorization scheme specifically developed for diagnosis-wide analysis. Further, we determined associations between the ABO/RhD blood groups and the age at the first diagnosis. Estimates were adjusted for multiple testing.

Results: The retrospective cohort included 482,914 Danish patients (60.4% females). The incidence rate ratios (IRRs) of 101 phecodes were found statistically significant between the ABO blood groups, while the IRRs of 28 phecodes were found statistically significant for the RhD blood group. The associations included cancers and musculoskeletal-, genitourinary-, endocrinal-, infectious-, cardiovascular-, and gastrointestinal diseases.

Conclusions: We found associations of disease-wide susceptibility differences between the blood groups of the ABO and RhD systems, including cancer of the tongue, monocytic leukemia, cervical cancer, osteoarthrosis, asthma, and HIV- and hepatitis B infection.. We found marginal evidence of associations between the blood groups and the age at first diagnosis.

Funding:; Novo Nordisk Foundation and the Innovation Fund Denmark.

Data availability

Anonymized patient data was used in this study. Due to national and EU regulations, the data cannot be shared with the wider research community. However, data can be accessed upon relevant application to the Danish authorities. The Danish Patient Safety Authority and the Danish Health Data Authority have permitted the use of the data in this study; whilst currently, the appropriate authority for journal data use in research is the regional committee ("Regionsråd"). The statistical summary data used to create the tables and graphs are available as Supplementary Data 1 and Supplementary Data 2. The analysis code is publicly available through www.github.com/peterbruun/blood_type_study.

Article and author information

Author details

  1. Peter Bruun-Rasmussen

    Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3595-1311
  2. Morten Hanefeld Dziegiel

    Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8034-1523
  3. Karina Banasik

    Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen N, Denmark
    Competing interests
    No competing interests declared.
  4. Pär Ingemar Johansson

    Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark
    Competing interests
    Pär Ingemar Johansson, has received grants from the AP Møller Foundation, Innovation Fund Denmark and Novo Nordisk Foundation. The author has been issued the following patents: Publication no: 20110201553, 20110268732, 20130040898, 20130261177, 20150057325, 20160113891, 9381166, 9381243, 20160250164, 9433589, 20160303040 and US20090053193A1. P.I. Johansson reports ownership of stocks in Trial-Lab AB, Endothel Pharma ApS, TissueLink ApS, and MoxieLab ApS. P.I. Johansson declares that the financial interests listed have no impact on the submitted work. The author has no other competing interests to declare. The author declares that the financial interests listed have no impact on the submitted work..
  5. Søren Brunak

    Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen N, Denmark
    For correspondence
    soren.brunak@cpr.ku.dk
    Competing interests
    Søren Brunak, participates on the Danish National Genome Center advisory board and is the Chairman for the data infrastructure board. The author has stock in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S and ALK Abello. The author participates on the board of directors for both Proscion A/S and Intomics A/S. The author has no other competing interests to declare. Søren Brunak declares that the financial interests listed have no impact on the submitted work..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0316-5866

Funding

Novo Nordisk Fonden (NNF14CC0001)

  • Søren Brunak

Novo Nordisk Fonden (NNF17OC0027594)

  • Søren Brunak

Innovation Fund (5153-00002B)

  • Søren Brunak

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: This is a register-based study and informed consent for such studies is waived by the Danish Data Protection Agency. Data access was approved by the Danish Patient Safety Authority (3-3013-1731), the Danish Data Protection Agency (DT SUND 2016-50 and 2017-57) and the Danish Health Data Authority (FSEID 00003092 and FSEID 00003724).

Copyright

© 2023, Bruun-Rasmussen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,033
    views
  • 179
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Peter Bruun-Rasmussen
  2. Morten Hanefeld Dziegiel
  3. Karina Banasik
  4. Pär Ingemar Johansson
  5. Søren Brunak
(2023)
Associations of ABO and rhesus d blood groups with phenome-wide disease incidence: a 41-year retrospective cohort study of 482,914 patients
eLife 12:e83116.
https://doi.org/10.7554/eLife.83116

Share this article

https://doi.org/10.7554/eLife.83116

Further reading

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Amanda C Perofsky, John Huddleston ... Cécile Viboud
    Research Article

    Influenza viruses continually evolve new antigenic variants, through mutations in epitopes of their major surface proteins, hemagglutinin (HA) and neuraminidase (NA). Antigenic drift potentiates the reinfection of previously infected individuals, but the contribution of this process to variability in annual epidemics is not well understood. Here, we link influenza A(H3N2) virus evolution to regional epidemic dynamics in the United States during 1997—2019. We integrate phenotypic measures of HA antigenic drift and sequence-based measures of HA and NA fitness to infer antigenic and genetic distances between viruses circulating in successive seasons. We estimate the magnitude, severity, timing, transmission rate, age-specific patterns, and subtype dominance of each regional outbreak and find that genetic distance based on broad sets of epitope sites is the strongest evolutionary predictor of A(H3N2) virus epidemiology. Increased HA and NA epitope distance between seasons correlates with larger, more intense epidemics, higher transmission, greater A(H3N2) subtype dominance, and a greater proportion of cases in adults relative to children, consistent with increased population susceptibility. Based on random forest models, A(H1N1) incidence impacts A(H3N2) epidemics to a greater extent than viral evolution, suggesting that subtype interference is a major driver of influenza A virus infection ynamics, presumably via heterosubtypic cross-immunity.

    1. Epidemiology and Global Health
    2. Genetics and Genomics
    Rashmi Sukumaran, Achuthsankar S Nair, Moinak Banerjee
    Research Article

    Burden of stroke differs by region, which could be attributed to differences in comorbid conditions and ethnicity. Genomewide variation acts as a proxy marker for ethnicity, and comorbid conditions. We present an integrated approach to understand this variation by considering prevalence and mortality rates of stroke and its comorbid risk for 204 countries from 2009 to 2019, and Genome-wide association studies (GWAS) risk variant for all these conditions. Global and regional trend analysis of rates using linear regression, correlation, and proportion analysis, signifies ethnogeographic differences. Interestingly, the comorbid conditions that act as risk drivers for stroke differed by regions, with more of metabolic risk in America and Europe, in contrast to high systolic blood pressure in Asian and African regions. GWAS risk loci of stroke and its comorbid conditions indicate distinct population stratification for each of these conditions, signifying for population-specific risk. Unique and shared genetic risk variants for stroke, and its comorbid and followed up with ethnic-specific variation can help in determining regional risk drivers for stroke. Unique ethnic-specific risk variants and their distinct patterns of linkage disequilibrium further uncover the drivers for phenotypic variation. Therefore, identifying population- and comorbidity-specific risk variants might help in defining the threshold for risk, and aid in developing population-specific prevention strategies for stroke.